ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Washington, DC, USA:

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma...

Active, not recruiting
Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma
Drug: Venetoclax
Drug: Ibrutinib

Phase 1, Phase 2

Georgetown University
Georgetown University

Washington, District of Columbia, United States and 2 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Baltimore, Maryland, United States and 88 other locations

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting
B Cell Lymphoma
Mantle Cell Lymphoma
Drug: Ibrutinib
Drug: Palbociclib

Phase 2

Alliance Foundation Trials

Baltimore, Maryland, United States and 8 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Fort Belvoir, Virginia, United States and 125 other locations

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Baltimore, Maryland, United States and 49 other locations

pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Baltimore, Maryland, United States and 2 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Enrolling
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

Genmab
Genmab

Washington, District of Columbia, United States and 52 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Mosunetuzumab
Drug: Obinutuzumab

Phase 1

ADC Therapeutics

Fairfax, Virginia, United States and 26 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Washington, District of Columbia, United States and 73 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Washington, District of Columbia, United States and 215 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems